{"gao_id": "GAO-17-143", "published": "2016-12-16T12:00:00Z", "released": "2017-01-17T07:00:00Z", "summary": "Much of the U.S. drug supply is manufactured overseas. FDA inspects drug manufacturing facilities around the world to ensure that their drugs are safe for the U.S. market. FDA uses a risk-based approach to select which manufacturing establishments to inspect\u2014prioritizing those that make drugs which, if defective, pose the greatest public health risk. In part to help its inspection efforts, FDA opened offices in China...", "title": "Drug Safety: FDA Has Improved Its Foreign Drug Inspection Program, but Needs to Assess the Effectiveness and Staffing of Its Foreign Offices", "topics": ["Strategic planning", "Pharmaceutical industry", "Manufacturing", "Drug safety", "Health Care", "Inspection", "Consumer protection", "Product safety", "International relations", "Foreign drug inspection", "Foreign drug manufacturing", "Performance measurement", "Drugs"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-17-143", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-17-143-highlights.pdf"}, {"title": "Full Report (63 pages)", "url": "https://www.gao.gov/assets/gao-17-143.pdf"}]}